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Guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs) 
regulate the activity of small guanine nucleotide-binding (G) proteins to control cellular 
functions. In general, GEFs turn on signaling by catalyzing the exchange from G-protein-
bound GDP to GTP, whereas GAPs terminate signaling by inducing GTP hydrolysis. GEFs 
and GAPs are multidomain proteins that are regulated by extracellular signals and local-
ized cues that control cellular events in time and space. Recent evidence suggests that 
these proteins may be potential therapeutic targets for developing drugs to treat various 
diseases, including cancer.Small G proteins are typically between 20–25 kDa in size 
and cycle between an inactive GDP-bound conformation 
and an active GTP-bound conformation. In their active 
conformation G proteins interact with effector proteins, 
which induce downstream signaling events. The GDP-
GTP cycle is highly regulated by GEFs that induce the 
release of the bound GDP to be replaced by the more 
abundant GTP and by GAPs that usually provide an 
essential catalytic group for GTP hydrolysis. Most small 
G proteins are modified at their C terminus by the addition 
of prenyl groups (such as farnesyl and geranylgeranyl), 
which act as lipid anchors and contribute to the locali-
zation of small G proteins to membranes. For a subset 
of small G proteins (mainly for Rab and Rho proteins) 
guanine nucleotide-dissociation inhibitors provide an 
additional level of control. These proteins remove small 
G proteins from membranes by sequestration of their 
lipid tails. In addition, certain Arf G proteins are localized 
by N-terminal myristoylation and acetylation.
The founding father of the small G-protein family is Ras, 
a protein mutated in 15% of all human tumors. The human 
Ras superfamily consists of at least 154 members divided 
into five principal families: the Ras, Rho, Rab, Arf, and 
Ran families (Wennerberg et al., 2005). These proteins 
control a wide variety of cellular processes. For example, 
Ran G proteins are responsible for nuclear import and 
export, the regulation of nuclear envelope formation, and 
the control of spindle formation. Members of the Rab and 
Arf families play important roles in vesicle-associated 
processes, ranging from vesicle formation and transport 
to exocytosis. The Rho family is mainly involved in the 
regulation of cell shape, the cytoskeleton, and cell migra-
tion, whereas Ras family members regulate a variety of 
signaling pathways, resulting in transcription and cellular 
differentiation and proliferation.The large number of G proteins requires a multitude of 
GEFs and GAPs to ensure signaling specificity. A number 
of selective GEF families exist. GEFs that regulate mem-
bers of the Ras family contain CDC25 homology domains 
(CDC25-HD), which occur in combination with a Ras 
exchange motif (REM). GEFs that regulate members of the 
Rho family contain a DH-PH tandem domain or an unre-
lated domain recently identified in DOCK proteins. GEFs 
for members of the Arf family contain a Sec7 domain, and 
the β-propeller protein RCC1 acts as a GEF for Ran. Vps9-, 
Sec2-, and Mss4-like proteins act as GEFs for members 
of the Rab family. Each individual GEF has a certain spe-
cificity profile for individual members of a G-protein family. 
In general, crossreactivity among members of different G-
protein families does not exist. Similarly, some GAP fami-
lies contain proteins that are structurally unrelated. Rho-
GAPs, Ran-GAPs, and Rab-GAPs act within their specific 
family of G proteins, whereas the unrelated Ras-GAPs and 
Rap-GAPs both act on proteins of the Ras family.
GEFs and GAPs have in common that they are usually 
multidomain proteins (Figure 1). Many of these domains 
are protein or lipid interaction domains, indicating that 
they serve as localization signals and/or as scaffolds for 
the formation of protein complexes. In some GEFs and 
GAPs, two different GEF or GAP domains are combined 
in one protein. This most likely has the purpose of pro-
viding an efficient means to interconnect the two signal-
ing processes.
In this review, we will highlight the molecular mecha-
nisms by which small G proteins are regulated by GEFs 
and GAPs. We will describe the mechanistic basis of 
the GEF and the GAP reactions and discuss how these 
activities are controlled in individual cases. Furthermore, 
we will explore whether GEFs or GAPs may make suit-
able drug targets.Cell 129, June 1, 2007 ©2007 Elsevier Inc. 865
Figure 1. GEFs and GAPs Are Multidomain Proteins
Representative GEFs and GAPs for the Rho, Ras, Rab, Ran, and Arf families are shown and named by their official gene symbol according 
to Entrez Gene (http://www.ncbi.nlm.nih.gov/). The catalytic domain, either the GEF or the GAP domain, is highlighted in yellow. RhoGEF 
domains (DH domains) almost always occur together with a PH domain (light yellow), and RasGEF domains (CDC25 homolog domains) almost 
always occur with REM domains (light blue). Some proteins contain two GEF or GAP domains for members of different G proteins. In these 
cases the proteins are shown twice (for each G-protein family), and the second GEF or GAP domain is highlighted in turquoise. Ras and Rap 
proteins belong both to the Ras family, but RasGAPs and RapGAPs are structurally unrelated. A couple of structurally unrelated RabGEFs 
exist. To indicate this, the catalytic domains are referred to as MSS4, Sec2, and VSP9, respectively. The domains are labeled according to the 
nomenclature of the SMART database (http://smart.embl-heidelberg.de). Not included in the list are GEFs and GAPs with less clear catalytic 
domains such as smgGDS and the Dock family.866 Cell 129, June 1, 2007 ©2007 Elsevier Inc.
Figure 2. Mechanism of GEF-Induced Nucleotide Exchange
(A) The exchange reaction occurs in successive reversible steps. The nucleotide (orange) interacts with the G protein (gray) via its base (B) and its 
phosphate moieties (P). The GEF (blue) competes with the nucleotide for binding with the G protein and thereby promotes nucleotide exchanges. 
The competition involves the existence of loose (subscript L) and tight (subscript T) interaction of the G protein with the nucleotide and the GEF.
(B) GEFs are structurally unrelated and have found individual ways to destabilize the G-protein nucleotide interaction. All G proteins (gray) are 
shown in the same orientation. The G proteins from the GEF complexes were superimposed on the respective G protein in complex with bound 
GDP (shown in ball-and-stick representation; orange). In regions where the structures of the nucleotide and the GEF-bound G proteins differ, the 
nucleotide-bound conformation is depicted in dark gray and the GEF bound structure in red. The GEF is shown in blue. Images are based on Protein 
Data Bank entries 2fu5 (Rab/Mss4), 2fol (Rab), 1foe (Rac/Tiam), 2g0n (Rac), 1bkd (Ras/Sos), 4q21 (Ras), 1i2m (Ran/RCC1), and 1byu (Ran).General Mechanism of GEFs
The affinity of most small G proteins for GDP/GTP is in 
the lower nanomolar to picomolar range. The direct con-
sequence of this high affinity is a slow dissociation rate 
of nucleotides with a half-life on the order of one or more 
hours. Because exchange of GDP for GTP and, thus, 
activation of G proteins in biological processes occur 
within minutes or even less, exchange of GDP for GTP 
requires the activity of GEFs. Indeed, GEFs accelerate 
the exchange reaction by several orders of magnitude 
(Vetter and Wittinghofer, 2001). The GEFs are often the 
targets of biological signals, which induce, inhibit, or 
modulate their catalytic activity.
GEFs catalyze the dissociation of the nucleotide 
from the G protein by modifying the nucleotide-bind-
ing site such that the nucleotide affinity is decreased 
and, thus, the nucleotide is released and subsequently 
replaced. In general the affinity of the G protein for GTP 
and GDP is similar, and the GEF does not favor rebind-
ing of GDP or GTP. Thus the resulting increase in GTP-
bound over GDP-bound is due to the approximately ten 
times higher cellular concentration of GTP compared 
to GDP. As shown first for the interaction between the RanGEF RCC1 and Ran the affinities of the binary com-
plexes between the G protein and either the nucleotide 
or its GEF are very high. In contrast, the affinities of the 
exchange factor for the nucleotide-bound G protein 
and of the nucleotide for the exchange-factor-bound G 
protein (the ternary complexes) are much lower (Vetter 
and Wittinghofer, 2001). Thus, the interaction of a GEF 
weakens the affinity for the nucleotide, and visa versa, 
the nucleotide weakens the affinity for the GEF. In the 
course of the exchange reaction the GEF displaces the 
bound nucleotide, and subsequently a new nucleotide 
displaces the GEF (Figure 2A).
How does the GEF weaken the affinity of the nucle-
otide? The G-protein-bound nucleotide is sandwiched 
between two loops called switch 1 and switch 2. The 
switch regions together with the phosphate-binding loop 
(P loop) interact with the phosphates and a coordinating 
magnesium ion. Both phosphates and the magnesium 
ion are essential for the high-affinity binding of the nucle-
otide to the G protein (Vetter and Wittinghofer, 2001). 
The action of the GEF on the G protein was analyzed in 
several structural studies. Due to the inherent instability 
of the ternary complexes most structural studies have Cell 129, June 1, 2007 ©2007 Elsevier Inc. 867
been performed with stable binary complexes between 
GEFs and G proteins (Boriack-Sjodin et al., 1998; Wor-
thylake et al., 2000; Renault et al., 2001; Goldberg, 1998; 
Itzen et al., 2006). These have revealed that the catalytic 
domains of the various families of GEFs are structurally 
unrelated and approach the G proteins from different 
angles (Figure 2B). However, they all use similar princi-
ples to deform the nucleotide-binding site. GEF binding 
induces conformational changes in the switch regions 
and the P loop, while leaving the remainder of the struc-
ture largely unperturbed. For instance, the CDC25-HD of 
SOS makes extensive contacts with switch 2 and uses 
an α-helical wedge to pry open the binding site (Figure 
2B; Boriack-Sjodin et al., 1998). RCC1 uses a β-turn on 
top of a β-propeller for insertion into the nucleotide-
binding site (Renault et al., 2001), whereas MSS4 binds 
via one of its β strands to switch 1 and thereby forms 
an intermolecular β sheet (Itzen et al., 2006; Figure 2B). 
In all these cases the interaction of the GEF sterically 
occludes the magnesium-binding site either by residues 
of the GEF or by the repositioning of the alanine side 
chain from the conserved DTAG motif of switch 2. This 
perturbs the interaction surface in the phosphate-bind-
ing region while leaving the base-binding region mostly 
unperturbed. As a consequence, the phosphate groups 
are released first after binding of the GEF, and the base 
of the entering nucleotide binds first when it starts to 
displace the GEF (Figure 2A). This model was supported 
by the structure of two ternary complexes. First, a com-
plex of Arf•GDP and the Sec7 domain of an ArfGEF was 
stabilized by the fungal toxin Brefeldin A. The structure 
of this complex shows how a glutamic acid finger of 
Sec7 approaches the negatively charged phosphates 
of GDP and thereby destabilizes phosphate binding 
(Renault et al., 2003). Second the structure of the ter-
nary complex between the catalytic PRONE domain of a 
plant RopGEFs in complex with Rop4•GDP shows that 
the magnesium-binding site is occluded by the alanine 
residue of the DTAG motif and that a glutamate in switch 
2 (E62 in H-Ras) points toward the phosphate group 
(Thomas et al., 2007). Considering that this glutamate is 
almost totally conserved in small G proteins and forms 
an ionic interaction in some binary complexes with the 
GEF, such as in the Ras-SOS (Boriack-Sjodin et al., 1998) 
and Dbs-Cdc42 complexes (Rossman et al., 2002), it 
appears that this residue is part of the driving force to 
reduce the affinity for the nucleotide. Thus, although the 
various GEFs are not conserved, their common action 
is to deform the phosphate-binding site, resulting in a 
reduced affinity of the nucleotide.
General Mechanism of GAPs
Although G proteins are also called GTPases, the 
actual GTP hydrolysis reaction is in fact very slow, 
and efficient hydrolysis requires the interaction with a 
GAP, which accelerates the cleavage step by several 
orders of magnitude. Several structural and biophysi-
cal studies have unraveled the reaction mechanism. In 868 Cell 129, June 1, 2007 ©2007 Elsevier Inc.the crystal structure of Ras in complex with GppNHp, 
a nonhydrolyzable GTP analog, a water molecule is 
positioned optimally for an in-line nucleophilic attack 
to the γ-phosphate opposite to the leaving group (here 
the GDP; Vetter and Wittinghofer, 2001; Figure 3A). 
Effective catalysis of phosphoryl transfer by GAPs con-
sists of several elements: the proper orientation of the 
attacking water molecule and its polarization, occlu-
sion of water from the active site, and the stabilization 
of the transition state. However, as with GEFs, GAPs 
for the different Ras-protein families are not conserved, 
approach the G protein from different angles, and use 
various ways to enhance the GTPase activity (Figures 
3B and 3C).
First insight into GAP-assisted GTP hydrolysis was 
obtained from the biochemistry and structure of the 
Ras-RasGAP complex (Scheffzek et al., 1997). Ras-
GAP stabilizes the position of glutamine 61 of Ras, 
which in turn coordinates the attacking water. In addi-
tion, an arginine, called the arginine finger, is posi-
tioned into the phosphate-binding site and stabilizes 
the transition state by neutralizing negative charge at 
the γ-phosphate. The arginine finger fulfils a function 
very similar to the arginine found in the helical insertion 
of α-subunits of large G proteins. This mechanism of 
catalysis is supported by biochemical and mutational 
studies. For instance, mutation of glutamine 61, which 
frequently occurs in human tumors, abolishes GAP-
induced hydrolysis. Oncogenic mutations at position 
12 and 13 of Ras sterically block the proper orientation 
of both the arginine finger and the glutamine 61 (Schef-
fzek et al., 1997). A similar mechanism was found for 
RhoGAP-assisted hydrolysis (Rittinger et al., 1997) 
even though RasGAP and RhoGAP are not related in 
terms of primary structure and are only distantly related 
in terms of tertiary structure (Figure 3B). The catalytic 
glutamine of Ras and Rho is also conserved in Rab, 
and the arginine finger is observed in RabGAP, but 
the mechanism is somewhat different. In this case the 
glutamine that orients the water is supplied by the GAP, 
and the glutamine of Rab is pointing away from the 
active site and is involved in the binding of GAP (Pan 
et al., 2006; Figure 3B). RanGAP supplies an asparag-
ine to stabilize the orientation of the glutamine of Ran 
(Seewald et al., 2002; Figure 3B). In contrast, Rap—a 
very close homolog of Ras—is lacking the correspond-
ing glutamine. Indeed RapGAP is structurally unrelated 
to RasGAP and provides an asparagine rather than an 
arginine residue as a major element of catalysis. It is 
postulated that this asparagine takes over the func-
tion of the glutamine to position the water molecule 
(Daumke et al., 2004). The catalytic glutamine is also 
not present in Sar. In this case a histidine from SarGAP 
positions the water molecule (Bi et al., 2002; Figure 
3B). Thus, the main contribution of different GAPs to 
catalysis is the stabilization of the intrinsically mobile 
catalytic machinery of the G protein and, in most cases, 
the insertion of a catalytic residue in trans.
Figure 3. Mechanism of GAP-Induced GTP Hydrolysis
(A) Schematic representation GTP hydrolysis assuming an in-line replacement reaction with an associative transition state and inversion of stere-
ochemistry of the γ-phosphate.
(B) Different GAPs use different ways to stimulate GTP hydrolysis. Residues of the G protein and the GAP that are directly involved in catalysis 
are shown in blue and red, respectively. The GTP is shown in the transition state of the hydrolysis. All figures are based on the crystal structure of 
the mentioned G protein in complex with the GAP and a slowly hydrolyzing GTP analog or GDP-aluminum fluoride with the exception of Rap and 
RapGAP, which is only a model based of the structure of Rap-GAP alone.
(C) GAPs are structurally unrelated. The G proteins (blue) of the Ras/RasGAP, Rho/RhoGAP, Ran/RanGAP, and Rab/RabGAP complexes were super-
imposed to each other, and thus all complexes are shown in the same orientation with respect to the G protein. The corresponding GAP is shown 
in red, and the bound GDP and Aluminiumfluoride are shown in ball-and-stick representation (orange). Images based on Protein Data Bank entries 
1wq1 (Ras/RasGAP), 1tx4 (Rho/RhoGAP), 1k5d (Ran/RanGAP), and 2g77 (Rab/RabGAP).Regulation of GEFs
Almost all GEFs are multidomain proteins regulated in a 
highly complex fashion. This regulation includes protein-
protein or protein-lipid interactions, binding of second 
messengers, and posttranslational modifications. These 
interactions and modifications induce either one or more of three major changes: a translocation to a spe-
cific compartment of the cell where the small G protein 
is located, the release from autoinhibition by a flanking 
domain or region, which covers the binding side for the 
small G protein, or the induction of allosteric changes in 
the catalytic domain.Cell 129, June 1, 2007 ©2007 Elsevier Inc. 869
Figure 4. Regulation of Exchange Factors by Masking of Binding Sites
(A) In Sos the access of RasGTP to the allosteric binding side is blocked by the DH domain. The structure of the REM-CDC25-HD fragment of Sos 
in complex with the allosteric Ras and the substrate Ras was superimposed to the structure of the Sos fragment containing the DH-PH-tandem and 
the REM-domain and CDC25-HD. The REM domain is shown in dark gray and the CDC25-homology domain in light gray. The Ras molecule bound 
to the catalytic site, which undergoes nucleotide exchange, is shown in blue, whereas the GTP-bound Ras bound to the allosteric site is shown in 
yellow. The DH domain, which occupies parts of the space that is required for binding of the allosteric Ras, is shown in red.
(B) In Epac the access of Rap to the catalytic site is blocked by the cAMP-binding domains. Ras (blue) was placed into the structure of the inactive 
Epac2 as a model for Rap based on the structure of Sos in complex with Ras. The REM domain and the CDC25-homology domain are shown in 
dark and light gray, respectively. The cAMP-binding domains, which block the catalytic site, are shown in red.
(C) In inactive Vav the access of Rac to the catalytic site is blocked by a short sequence directly N-terminal to the DH domain. The core of the DH 
domain is shown in gray and the N-terminal auto-inhibitory sequence in red. Tyr174, which is orientated inside a hydrophobic grove formed by the 
DH domain and which undergoes phosphorylation in the activation process of Vav, is shown in ball-and-stick representation. Rac (blue) is modeled 
into the structure based on the complex of Rac and Tiam. 
Images based on Protein Data Bank 1nvu (Ras), 1xd4 (Sos fragment), 2byv (Epac2), 1bkd (Sos/Ras complex), 1f5x (Vav), and 1foe (Rac/Tiam 
complex).Regulation by Protein Interactions: The Sos 
Paradigm
Sos1 and Sos2 combine GEF activity toward Rac and 
Ras because they consist of an N-terminal histone-
binding domain followed by a DH-PH domain specific 
for Rac, a REM domain, a CDC25-HD specific for Ras, 
and a C-terminal proline-rich region. Sos is regulated 
by recruitment to the plasma membrane where Ras is 
located. This translocation is mediated by Grb2, a SH3-
SH2-SH3-domain-containing adaptor protein that binds 
with its SH3 domains to the proline-rich region of Sos and 
with its SH2 domain to tyrosine-phosphorylated recep-
tors or receptor-associated adaptor proteins (Aronheim 
et al., 1994). This translocation is under negative feed-
back control by the kinase ERK, which phosphorylates 
Sos resulting in its dissociation from Grb2 (Waters et al., 
1995). Just as Sos is recruited to receptors by the adap-
tor protein Grb2, C3G, a GEF for the Ras-family mem-
ber, Rap, is similarly recruited by the adaptor protein Crk 
(Tanaka et al., 1994).
Differential regulation of Ras versus Rac activity of 
Sos is mediated by mutually exclusive interactions with 
adaptor proteins in vivo. Ras-GEF activity requires the 
interaction of Sos with Grb2 (Aronheim et al., 1994). 
Rac-GEF activity requires the interaction of Sos with a 
complex of Abi1/E3B1, Eps8, and PI3K (Innocenti et al., 
2003). However, the interactions of Sos with Grb2 and 870 Cell 129, June 1, 2007 ©2007 Elsevier Inc.of Sos with Abi1/E3B1 are both mediated by the same 
region of Sos and are thus mutually exclusive (Innocenti 
et al., 2002). In addition, p66Shc competes with Sos for 
the interaction with Grb2 and thus drives Sos into the 
Abi1/E3B1 complex (Khanday et al., 2006).
Additionally, the Ras-GEF activity of Sos is allosteri-
cally regulated by RasGTP, which binds to a second 
allosteric binding site constituted by parts of the REM 
and CDC25-HD (Margarit et al., 2003). This binding 
site is distinct from the catalytic site in the CDC25-
HD, which catalyzes nucleotide exchange toward 
Ras. In vitro, binding of RasGTP to the allosteric site 
induces a 10-fold increase in the catalytic activity of 
a Sos protein lacking the DH-PH domain (Margarit et 
al., 2003), and in vivo signal from ERK is enhanced 
by this positive feedback (Boykevisch et al., 2006). In 
the crystal structure of a fragment containing the DH-
PH, the REM, and the CDC25-HD, the allosteric site 
is blocked by the DH domain, and consequently no 
stimulation of RasGEF activity by RasGTP is observed 
for full-length Sos in vitro (Sondermann et al., 2004; 
Figure 4A). How this blockage of the allosteric site by 
the DH domain is lifted is currently unclear, but it may 
include the binding of the PH domain to membranes 
or interaction with other regulatory proteins. In this 
context, it is interesting to note that the PH domain of 
Sos blocks the binding site of Rac to the DH domain, 
and, thus, relatively large structural rearrangements 
within the DH-PH domain are expected (Soisson et al., 
1998; Sondermann et al., 2004; see below). In addi-
tion, deletion of the C-terminal proline-rich region of 
Sos increases Ras-GEF activity, suggesting that this 
region plays an inhibitory role in addition to Grb bind-
ing (Aronheim et al., 1994). The structural basis for 
this effect is currently unclear.
Thus, all three elements of regulation are realized 
in Sos: translocation to tyrosine-phosphorylated pro-
teins, autoinhibition by both C-terminal and N-terminal 
domains, and an allosteric, positive feedback regulation 
by RasGTP. Importantly, most of the gain-of-function 
germline mutations in the Sos gene found in patients 
with Noonan syndrome (which causes abnormal devel-
opment of multiple parts of the body) are located in regu-
latory regions of the molecule rather than the Cdc25-HD, 
supporting the regulatory role of these domains (Tarta-
glia et al., 2007; Roberts et al., 2007).
Regulation by Protein Interactions: Variations of a 
Theme
A prominent example of allosteric GEF activation by 
protein-protein interaction is p115RhoGEF/LARG, which 
couples G-protein-coupled receptor (GPCR) signaling to 
Rho activation. p115RhoGEF contains a RGS (regulator 
of G-protein signaling) domain, which binds to the Gα12 
and Gα13 subunits of heterotrimeric G proteins. This 
interaction induces RhoGEF activity and at the same 
time stimulates the GTPase activity of the Gα subunit 
(reviewed by Fukuhara et al., 2001).
A classical way to regulate GEF translocation is for 
a GEF that regulates a particular downstream G pro-
tein to interact with an upstream GTP-bound G protein. 
This principle is conserved in evolution. For example, 
the yeast G protein Bud1 binds to CDC24, a GEF for 
CDC42 (Kozminski et al., 2003). In human the most 
notable examples are GEFs for Ral, such as RalGDS or 
Rlf. These GEFs contain a CDC25-HD, which acts spe-
cifically on Ral, and in addition a Ras-association (RA) 
domain, which interacts with the GTP-bound states of 
Ras and Rap. Ras induces the translocation of RalGDS 
to the plasma membrane and thereby increases Ral-
GTP levels (Urano et al., 1996). This increase is most 
likely due to the translocation, as the same increase 
is observed when RalGDS is artificially targeted to the 
plasma membrane.
In a similar way, the RabGEFs Rin1, Rin2, and Rin3 
contain an RA domain. Rin1 specifically binds to Ras-
GTP after Ras activation by receptor tyrosine kinases, 
which typically leads to the activation of ERK via the 
MAP kinase pathway. The additional activation of Rab5 
via Rin enhances endocytosis of the membrane recep-
tor, which is subjected to degradation in lysosomes, and 
thus a negative feedback loop is established (Tall et al., 
2001). Finally, Tiam1, a GEF for the Rho family, contains 
an RA domain, which specifically binds to RasGTP and 
thereby links Ras signaling to Rac signaling (Lambert et 
al., 2002).Second Messenger Regulation
A number of GEFs are directly regulated by common 
second messengers, such as cAMP, Ca2+, and dia-
cylglycerol (DAG). Most notable are two GEFs for Rap 
proteins, Epac1 and Epac2, that are directly activated 
by cAMP. Epac1 has a single cyclic nucleotide-binding 
(CNB) domain, whereas in Epac2 an additional N-ter-
minal CNB domain is found, which is not required for 
the regulation of Epac 2 in vitro (Bos, 2006). Recently 
the crystal structure of Epac2 was solved in the inac-
tive conformation (Rehmann et al., 2006). Comparison 
with the crystal structure of the Sos-Ras-complex (Bori-
ack-Sjodin et al., 1998) revealed that the CNB domains 
cover the binding site for Rap (Rehmann et al., 2006; 
Figure 4b). This implies that binding of cAMP induces a 
conformational change that results in solvent exposure 
of the Rap-binding site. Indeed, mutational analysis of 
the interface between the regulatory and catalytic region 
supports this model (Rehmann et al., 2006). The cellu-
lar localization of Epac is controlled by protein-protein 
interactions despite direct regulation by cAMP. Epac2 
for example contains an RA domain, which was shown 
to interact with H-Ras (Li et al., 2006).
A number of GEFs respond to Ca2+, diacylglycerol 
(DAG), or both. Most notable are RasGRP1, RasGRP2, 
RasGRP3, and RasGRP4, which activate either Ras, 
Rap, or both. Members of the RasGRP family are char-
acterized by an N-terminal REM and Cdc25 homology 
domain followed by C-terminal C1 domain and a pair of 
EF-hands (Ebinu et al., 1998). In vivo RasGRPs induce 
Ras and/or Rap activation in response to increased con-
centration of Ca2+ and DAG, and RasGRP1 is recruited 
to DAG-rich membranes (Ebinu et al., 1998). The impor-
tance of proper localization for the biological function 
of RasGRPs is further demonstrated by the finding that 
RasGRP1 mediates the activation of Ras at the Golgi 
(Bivona et al., 2003) and that the localization of RasGRP2 
at the plasma membrane is F actin dependent (Caloca 
et al., 2004). Interestingly a splice variant of RasGRP2 is 
myristoylated and palmitoylated at its N terminus, which 
allows a DAG-independent membrane localization 
(Clyde-Smith et al., 2000). It is currently unclear whether 
RasGRPs are in general allosterically regulated by Ca2+ 
or DAG.
As indicated, the catalytic region of most RhoGEFs 
consists of a conserved DH/PH domain tandem (Ross-
man et al., 2005). The DH domain interacts with the G 
protein and mediates the GEF activity. The function of 
the PH domain—commonly considered to be a phos-
phatidylinositol phosphate-binding protein domain—is 
surprisingly divergent in the individual GEFs. Indeed 
structural analysis has shown that the relative orienta-
tion of the PH domain toward the DH domain is com-
pletely different in various GEFs (Rossman et al., 2005). 
As a consequence the PH domain has different func-
tions. As indicated, in Sos the PH domain has an autoin-
hibitory function, whereas in Dbs and PDZ-RhoGEF the 
PH domain interacts with the G protein and enhances Cell 129, June 1, 2007 ©2007 Elsevier Inc. 871
catalytic activity. To what extent phosphatidylinositol 
phosphate (PIP) binding to the PH domain influences 
catalytic activity or contributes to membrane anchoring 
is not entirely clear and might be different for the indi-
vidual PH domains. For instance, Sos was reported to 
be regulated only moderately by PIP3 (Han et al., 1998), 
whereas Intersectin, Dbs, and Tiam1 failed to show any 
influence of PIP on GEF activity (Snyder et al., 2001). 
Indeed, residues involved in ligand interaction of lipid-
binding PH domains are only poorly conserved in DH-
PH domains.
Posttranslational Modification
Several members of the RhoGEF family are character-
ized by an autoinhibitory region directly N-terminal to the 
DH domain. It was identified based on the observation 
that N-terminal truncated versions of these GEFs have 
transforming properties (Schmidt and Hall, 2002). Best 
characterized in this respect is the Vav group, which 
activates members of the Rho family. These proteins 
consist of three regions, an N-terminal autoinhibitory 
region with a calponin homology (CH) domain and an 
acidic (Ac) region with conserved tyrosines, a central 
catalytic region with a DH-PH domain and a C-terminal 
recruitment region with a Zn-finger domain, a proline-
rich sequence, and an SH3-SH2-SH3 module (Turner 
and Billadeau, 2002). As determined by single-parti-
cle electron microscopy the inactive conformation of 
the protein has a closed conformation with the CH-Ac 
domain close to the DH domain at the binding site for 
Rac (Llorca et al., 2005). Indeed, NMR studies revealed 
interactions between a part of the Ac region adjacent 
to the DH domain that contains a conserved tyrosine 
(Tyr 174 in Vav1) (Aghazadeh et al., 2000). Tyr174 points 
inside a hydrophobic pocket in the DH domain, and its 
phosphorylation disrupts the interaction between the Ac 
region and the DH domain, thereby liberating the cata-
lytic site (Figure 4C). This phosphorylation is mediated 
by Lck- and Src-like kinases.
Vav is recruited to tyrosine-phosphorylated adaptor 
proteins through its SH2 domain. Interestingly, the Zn-
finger domain serves as a docking site for Rho proteins 
(Movilla and Bustelo, 1999). Recently it was found that Vav 
binds to Rap1 through its DH-PH domain and serves as 
an effector of Rap1 in cell adhesion (Arthur et al., 2004).
A number of Rho-GEFs have a region adjacent to the DH 
domain that is similar to the acidic region in Vav. Indeed, 
as shown for TIM, potent activation of catalytic activity can 
be achieved by N-terminal truncations “mimicking” a natu-
ral phosphorylation event. Interestingly, a peptide derived 
from the N-terminal motif can be used in trans to inhibit 
GEF activity suggesting a putative therapeutic approach to 
inhibit this class of RhoGEFs (Yohe et al., 2007).
Regulation of GAPs
GAPs are regulated by either protein-protein or protein-
lipid interactions, binding of second messengers, and/or 
posttranslational modifications. These interactions and 
modifications induce translocations to the site where the 872 Cell 129, June 1, 2007 ©2007 Elsevier Inc.small G protein is located and release from autoinhibi-
tion by a flanking domain and, in some cases, allosteric 
modification of the catalytic activity.
Protein Translocation and Complex Formation
RasGAP (p120GAP) was the first protein to be identified 
as a GAP. In addition to the GAP domain RasGAP con-
tains SH2, SH3, PH, and C2 domains, and initial stud-
ies suggested that RasGAP, through its SH2 domains, 
can associate with receptor tyrosine kinases to become 
phosphorylated. However, to what extent RasGAP is 
regulated has remained unclear (Bernards and Settle-
man, 2004).
Neurofibromatosis is an autosomal dominant dis-
ease, which is caused by mutations in the neurofibromin 
gene. Neurofibromin is a protein 320 kDa in size, which 
contains a central RasGAP domain (contributing only 
?15% of the total size). The remaining sequence lacks 
any recognized domains, except for a phospholipid-
binding Sec14-PH module immediately adjacent to the 
GAP domain (D’Angelo et al., 2006). However, missense 
mutations found in Neurofibromatosis patients are dis-
tributed over almost the entire gene, indicating that other 
functional domains are likely to exist and contribute to 
function (Bernards and Settleman, 2004).
Regulation by protein-protein interaction is also 
observed for an N-terminally extended splice variant of 
RapGAP, which has gained a GoLoco motif. Through 
this domain Rap1GAP specifically binds to the activated 
form of Gi, resulting in the activation of GAP activity 
(Mochizuki et al., 1999). Whether this is due to trans-
location toward Rap1 or due to allosteric regulation is 
currently unknown. Similarly, Rap1GAP also binds to the 
inactive form of Go, but this results in the inactivation of 
Rap1GAP (Jordan et al., 1999).
RA-RhoGAP has in addition to the RhoGAP domain 
an RA domain and a PH domain. The GAP activity is 
induced by Rap1, which binds to the RA domain. In addi-
tion deletion of the RA domain also activates the protein 
suggesting that it serves as an autoinhibitory sequence 
that is released by binding to Rap1. Indeed RA-RhoGAP 
functions as an effector of Rap1 in the control of neurite 
outgrowth (Yamada et al., 2005).
Similarly, proteins of the ARAP family contain a 
RhoGAP and an ArfGAP domain in addition to several 
PH domains and an RA domain. ARAP proteins are 
regulated at different levels. Whereas in vitro ArfGAP 
activity is induced by PI(3,4,5)P3 and PI(3,4)P2, phosph-
oinositols have no influence on RhoGAP activity (Miura 
et al., 2002). Instead, binding of Rap1 to the RA domain 
enhances RhoGAP activity (Krugmann et al., 2004).
Second Messenger Regulation
The Gap1 family of RasGAPs is constituted by Gap1, 
CAPRI, RASAL, and GAPIP4BP. The central catalytic 
domain is flanked by two N-terminal C2 domains and 
a C-terminal PH domain. CAPRI, RASAL, and GAPIP4BP 
show dual specificity for Ras and Rap (Cullen and Lock-
yer, 2002; Kupzig et al., 2006). This is a surprising finding 
considering the different catalytic mechanisms of Ras-
GAPs and RapGAPs. Yet, for both activities the catalytic 
arginine finger, typical of RasGAPs, is required. However, 
the RapGAP activity strongly depends on sequences 
flanking the RasGAP domain. How the specificity for 
Rap1 is induced awaits structural information of the 
complex but is likely to involve interactions between the 
domains (Kupzig et al., 2006). C2 domains often mediate 
Ca2+-dependent membrane targeting, and indeed Ca2+ 
induces the translocation of CAPRI and RASAL to the 
plasma membrane. However both proteins decode Ca2+ 
differently: RASAL follows Ca2+ fluctuations linearly by 
repetitively oscillating between membrane and cytosol, 
whereas CAPRI remains associated with the membrane 
after a pulse of Ca2+ (Liu et al., 2005). Different functions 
are suggested for the PH domains of the GAP1 family. 
GAP1 is recruited to the plasma membrane by binding 
of the PH domain to PIP3 after activation of PI3K. Trans-
location seems to be the sole mechanism of GAP activa-
tion because lipid binding did not affect GAP1 activity. 
In contrast, GAPIP4BP is constitutively membrane bound 
but requires binding of inositol 1,3,4,5 tetraphosphate, 
the PLC-mediated cleavage product of PIP3 to its PH 
domain for GAP activity (Cullen and Lockyer, 2002).
β2-chimaerin, a GAP for Rac, contains an SH2 
domain, a C1 domain responsible for DAG binding, and 
a RhoGAP domain. Binding of DAG results in the trans-
location of β2-chimaerin to the plasma membrane, and 
evidence for a direct enhancement of GAP activity by 
DAG binding was obtained from in vitro analysis (Caloca 
et al., 2003). In the crystal structure of full length β2-chi-
maerin the DAG-binding site is partially covered by the 
N terminus of the protein, and the extreme N terminus, 
which is flexible in the structure, seems to extend into 
the binding site for Rac in the GAP domain. Thus binding 
of DAG is assumed to release this block of the active site 
(Canagarajah et al., 2004).
Posttranslational Modification
The small G protein Rheb has a central function in path-
ways that control cell growth via regulation of the serine-
threonine kinase mTor. Rheb is largely regulated through 
the modulation of the protein complex TSC1/TSC2 (also 
known as hamartin and tuberin). Although TSC2 carries 
the GAP domain for Rheb, it apparently requires TSC1 
as a stabilizing factor for activity.
The GAP activity of TSC2 is regulated on different 
levels. First, TSC2 is phosphorylated on a multitude of 
serine and threonine residues by a variety of kinases 
resulting in the inactivation of GAP activity. For instance, 
Akt/Protein kinase B, which mediates insulin signaling 
to mTOR, phosphorylates TSC2 at Ser939 and Thr1462. 
Other kinases that phosphorylate and inactivate TSC2 
are ERK, PKC, and Rsk, indicating that multiple path-
ways converge on TSC2 (Avruch et al., 2006). Recently 
tyrosine phosphorylation of TSC2 by FAK was demon-
strated, and, thus, Rheb-mediated cell growth is fine-
tuned by the adhesion state of the cell (Gan et al., 2006). 
Secondly, TSC1/TSC2 is positively regulated by AMP-
activated protein kinase (AMPK). This kinase monitors the ATP/AMP ratio as a measure of cellular energy level. 
At low levels of energy AMPK phosphorylates TSC2 on 
Thr1227 and Ser1345 thereby enhancing its GAP activ-
ity (Inoki et al., 2003). In addition, Gsk3 activates TSC2 
by phosphorylation on Ser1337 and Ser1341, which may 
need AMPK as a priming kinase. Thirdly, the stability 
of the TSC1/TSC2 complex may be regulated result-
ing either in the release of TSC2 from the complex or in 
TSC2 degradation (Aicher et al., 2001).
Are GEFs and GAPs Suitable Drug Targets?
Since the discovery 20 years ago that Ras is mutated in 
many human tumors, one of the great challenges in can-
cer therapeutics has been to find an inhibitor selective for 
“oncogenic” Ras. Back then, the only feasible approach 
was to interfere with the membrane localization of Ras 
by blocking the machinery that provides the lipid anchor 
for Ras. Thus, many pharmaceutical companies devel-
oped programs to discover farnesyl transferase inhibi-
tors and, after the discovery that K-ras was also gera-
nyl-geranylated, to identify geranyl-geranyl transferase 
inhibitors. However, these inhibitors also affect normal 
Ras in nontumor cells and, as we now realize, a wide 
variety of Ras-like small G proteins. Indeed, although 
some of these inhibitors have clinical benefits, none are 
specific for “oncogenic” Ras. With the success of kinase 
inhibitors, such as imatinib, which blocks bcr-abl, the 
notion of directly targeting the regulatory machinery of 
small G proteins has faded. This is largely due to the lack 
of clear binding pockets at the active sites of GEFs and 
GAPs for binding of a small molecule. However, there is 
evidence that GEFs and perhaps GAPs can be targeted 
by small molecules.
Inhibitors of GEFs
ArfGEFs can be divided in two groups: large ArfGEFs 
(?200 kDa), represented by BIG1 and BIG2, and small 
ArfGEFs (?45 kDa), represented by ARNO and Cyto-
hesin. In addition to the catalytic Sec7 domain both 
groups contain a PH domain. The activity of the large 
ArfGEFs was found to be inhibited by the natural com-
pound Brefeldin A, resulting in the collapse of the Golgi 
structure. Brefeldin A stabilizes the ternary ARF-GDP-
GEF complex and thus traps the GEF in an unproductive 
complex with its substrate. Structural analysis revealed 
that Brefeldin A binds at the binding interface between 
the Sec7 domain and Arf1 and thereby stabilizes the 
interaction (Renault et al., 2003).
An elegant approach to identify inhibitors for GEFs was 
recently reported for the small ArfGEFs. M69 was identified 
in a library of RNA aptomers due to its ability to inhibit Cyto-
hesin-1 activity in vitro (Mayer et al., 2001). Subsequently, 
a chemical library was screened for molecules that could 
compete with M69 for binding to Cytohesin-1 resulting 
in identification of SecinH3. SecinH3 inhibited the ARNO 
and Cytohesin-1 with an IC50 in the low micromolar range 
in vitro. Interestingly, using this inhibitor it was found that 
cytohesins play a role in insulin signaling, demonstrating its 
applicability for in vivo systems (Hafner et al., 2006).Cell 129, June 1, 2007 ©2007 Elsevier Inc. 873
Some truncated RhoGEFs, lacking their autoinhibitory 
regions, have a transforming potential. Although such 
truncations were not found in tumors, the dominant 
mutation A441G in the PH domain of Tiam was found 
in 3 out of 30 primary renal cell cancers and in 1 out of 
5 cell lines and was shown to increase the transform-
ing capabilities of Tiam1 in NIH-3T3 cells (Engers et al., 
2000). RhoGEFs are thus putative anticancer targets. 
The compound NSC23766 was identified by a virtual 
screen based on the structure of the Tiam-Rac complex 
as an inhibitor of the interaction between Rac and Tiam 
and Rac and Trio. Indeed, NSC23766 inhibits specifically 
Rac-induced events, like the formation of lamellipodia, 
cell proliferation, and anchorage-independent growth in 
vivo (Gao et al., 2004). Tiam1 knockout mice have no 
obvious phenotype, except that the induction of tumors 
by carcinogens is reduced (presumably due to increased 
apoptosis) and tumors grow slower than similar tumors 
in wild-type mice (Malliri et al., 2002). This may imply that 
inhibition of Tiam1 might be well tolerated by healthy tis-
sues. Also, chemical inhibitors of the Rho-GEF domain 
of Trio (Trio-GEFD1) have been identified using a yeast-
selection system (Blangy et al., 2006). However the rel-
evance of these inhibitors as drugs is currently unclear.
These examples demonstrate that the inhibition of 
GEFs is in principle possible and that several differ-
ent approaches can be used, i.e., the inhibition of the 
interaction between the GEF and its G protein and the 
stabilization of the interaction between the GEF and its 
G protein. In particular the second approach of “inter-
facial inhibition” (Renault et al., 2003) is interesting 
because the compound does not have to compete with 
the natural substrate, and, thus, relatively low affinities 
may be sufficient for efficient inhibition. In addition, such 
inhibitors may be highly selective because they bind to 
a specific interaction site between two proteins. Other 
examples of “interfacial inhibitors,” which are already 
in clinical use, are the natural products rapamycin and 
cyclosporine A. Rapamycin targets the kinase mTOR by 
stabilizing a complex between mTOR and FKBP12, and 
cyclosporine A targets the phosphatase calcineurin by 
forming a complex with cyclophilin.
Activators of GEFs
For certain GEFs, such as the Epac proteins, activation 
rather that inhibition may have therapeutic benefits. These 
Rap-GEFs are activated by direct binding of cAMP and, 
among others, are involved in the formation of cell-cell 
junctions (Bos, 2006). Junctions are critically important 
for the integrity of epithelial and endothelial monolayers, 
and leakage results in severe damage, as occurs in sep-
tic shock, respiratory distress syndrome, and edema. 
A selective agonist of Epac, 8-pCPT-2′OMe-cAMP, has 
been developed (Enserink et al., 2002) that counteracts 
a decrease in endothelial permeability caused by leak-
age-inducing agents such as thrombin and VEGF. 8-
pCPT-2′OMe-cAMP was shown to inhibit vessel leakage 
in the skin of a mouse after a challenge with VEGF (Fuku-
hara et al., 2005). In pancreatic β cells Epac2 mediates 874 Cell 129, June 1, 2007 ©2007 Elsevier Inc.the modulation of glucose-induced insulin secretion by 
glucagon-like peptide (Ozaki et al., 2000). Treatment of 
these cells with 8-pCPT-2′OMe-cAMP results in insulin 
secretion, indicating that a selective agonist for Epac2 
may be an alternative of glucagon-like peptide receptor 
agonists (Bos, 2006).
Other Potential Therapeutic Targets
One of the holy grails in cancer research is to find 
selective inhibitors of mutant Ras. One of the hall-
marks of oncogenic Ras is the presence of mutations 
that abolish RasGAP-induced GTP hydrolysis. How-
ever, similar mutations in Rap1 do not prevent Rap-
GAPs from hydrolyzing GTP-bound to Rap1 because 
the catalytic mechanism of RasGAP differs from the 
catalytic mechanism of RapGAP. Perhaps it is pos-
sible to redirect RasGAP to induce GTP hydrolysis on 
oncogenic Ras or even to redirect RapGAP to bind 
to and hydrolyze GTP bound to mutant Ras. Alterna-
tively, small molecules may be developed that induce 
GTP hydrolysis on oncogenic Ras. Such molecules 
may not need to be as effective as real GAPs, as 
transformation experiments with different mutants of 
the Gly12 position of Ras (one of the few residues that 
is typically found mutated in cancer) have shown that 
a relatively low residual GTPase activity is sufficient to 
prevent transformation (Eccleston et al., 1993).
Inhibition of the Sos-Ras interaction may be an 
approach to combat tumors with constitutively active 
receptor tyrosine kinases, such as the EGF receptor 
and HER2 receptor in breast tumors. One option is to 
screen for inhibitors that interfere directly in the Sos-
Ras interaction, as shown for the Tiam1-Rac interaction. 
An alternative is to identify compounds that stabilize 
the autoinhibitory conformation. Another potential drug 
target is Vav1, which was recently found to be upregu-
lated in most pancreatic tumor cell lines and in about 
50% of the pancreatic ductal adenocarcinomas due 
to promotor demethylation (Fernandez-Zapico et al., 
2005). Vav1 overexpression is associated with poorer 
survival. Furthermore, inhibition of Vav1 by siRNA abro-
gates neoplastic proliferation of pancreatic cells and 
induces apoptosis even in the presence of oncogenic 
Ras. Although the related Vav2 was also expressed in 
pancreatic cells, inhibition of Vav2 with siRNA did not 
affect neoplastic proliferation and survival, stressing 
the specificity of the Vav1 protein in this process (Fer-
nandez-Zapico et al., 2005). Structural analysis of the 
Vav3 protein revealed that in the unbound conforma-
tion the N-terminal CH domain opposes the Rac-bind-
ing site. It may be that a compound that stabilizes the 
CH domain to the PH-DH domain is sufficient to inhibit 
Vav proteins specifically. Importantly, Vav1 knockout 
mice are viable, with only impaired immune function, 
and even mice deficient for all three Vav isotypes are 
viable (Fujikawa et al., 2003).
Another interesting target is RalGDS. RalGDS is a 
downstream effector of Ras involved in Ras-medi-
ated oncogenic transformation (Coleman et al., 2004). 
Knockout mice have limited defects but show greatly 
reduced tumorigenicity in a skin-tumor model (Gonza-
lez-Garcia et al., 2005). Similarly, PLCε knockout mice 
are also viable and show reduced induction of tumors 
following carcinogen treatment and Ras activation (Bai 
et al., 2004).
Also, the Rap-specific RasGRP2 may be a potential 
drug target, as knockout mice show that platelets are 
severely compromised in integrin-dependent aggrega-
tion (Crittenden et al., 2004). This suggests that a drug 
that inhibits RasGRP2 may be beneficial in the treatment 
of hyperactive platelet aggregation. For this GEF, com-
pounds that interfere in the binding with diacylglycerol or 
Ca2+ might be used to prevent membrane targeting.
Future studies should be devoted to further validate 
GEFs and GAPs as therapeutic targets. In addition the 
molecular mechanism of activation should be elucidated, 
including the crystal structures of active and inactive 
conformations so as to design mechanisms of interfer-
ence. Potential compounds might then be identified by 
virtual or high-throughput screening using proper assay 
systems. Given the versatile roles of GEFs and GAPs in 
signal transduction and disease much might be gained 
in following this approach.
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